Literature DB >> 17082510

Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

O Trédan1, J-F Geay, S Touzet, R Delva, B Weber, J Cretin, J Provencal, J Martin, L Stefani, E Pujade-Lauraine, G Freyer.   

Abstract

BACKGROUND: To determine the feasibility of two chemotherapy regimens in elderly patients with advanced ovarian carcinoma (AOC). PATIENTS AND METHODS: Eighty-three patients >or=70 years were previously enrolled in a trial evaluating carboplatin and cyclophosphamide (CC). On the basis of identical eligibility criteria, 75 further patients were enrolled in a trial evaluating carboplatin and paclitaxel (Taxol) (CP). The primary end point of these studies was the feasibility of six courses of chemotherapy. Comprehensive geriatric assessment (CGA) parameters were assessed in terms of prognostic factors.
RESULTS: More patients in the CC group presented with performance status of two or more, depression symptoms, use of co-medications, hypoalbuminemia, abnormal Mini-Mental Status score, or sub-optimal surgery. Both regimens appeared feasible: 75.6% in the CC group and 68.1% in the CP group completed six courses. CC and CP groups had similar overall survival (OS). Independent prognostic factors of poorer OS were the following: increasing age (P = 0.013), depression symptoms at baseline (P < 0.001), International Federation of Gynecology and Obstetrics stage IV (P = 0.001), and use of paclitaxel (P = 0.025).
CONCLUSION: As this is a non-randomised retrospective review of two consecutive studies, no firm conclusion can be drawn. It seems, however, that in elderly patients with AOC the use of paclitaxel results in more toxicity. CGA parameters and particularly emotional disorders might help to determine a priori the risk/benefit ratio of chemotherapy in this patient population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082510     DOI: 10.1093/annonc/mdl400

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  15 in total

1.  Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Helen Q Huang; Jan H Beumer; Heather A Lankes; William Tew; Thomas Herzog; Arti Hurria; Robert S Mannel; Tina Rizack; Lisa M Landrum; Peter G Rose; Ritu Salani; William H Bradley; Thomas J Rutherford; Robert V Higgins; Angeles Alvarez Secord; Gini Fleming
Journal:  Gynecol Oncol       Date:  2017-01-13       Impact factor: 5.482

2.  Safety and tolerance of radical hysterectomy for cervical cancer in the elderly.

Authors:  Erin M George; Ana I Tergas; Cande V Ananth; William M Burke; Sharyn N Lewin; Eri Prendergast; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2014-04-24       Impact factor: 5.482

Review 3.  The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer.

Authors:  Marije E Hamaker; Alinda G Vos; Carolien H Smorenburg; Sophia E de Rooij; Barbara C van Munster
Journal:  Oncologist       Date:  2012-08-31

4.  Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).

Authors:  Annelot G J van Rossum; Ingrid A M Mandjes; Erik van Werkhoven; Harm van Tinteren; A Elise van Leeuwen-Stok; Petra Nederlof; Johanna E A Portielje; Robbert J van Alphen; Els Platte; Daan van den Broek; Alwin Huitema; Marleen Kok; Sabine C Linn; Hendrika M Oosterkamp
Journal:  Breast Care (Basel)       Date:  2021-01-22       Impact factor: 2.860

5.  Doublet chemotherapy in the elderly patient with ovarian cancer.

Authors:  Min Y Teo; Derek G Power; William P Tew; Stuart M Lichtman
Journal:  Oncologist       Date:  2012-08-22

6.  Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer.

Authors:  William P Tew
Journal:  Curr Treat Options Oncol       Date:  2013-03

7.  Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer.

Authors:  Wadih Rhondali; Gilles Freyer; Virginie Adam; Marilène Filbet; Martine Derzelle; Gaelle Abgrall-Barbry; Sophie Bourcelot; Jean-Louis Machavoine; Muriel Chomat-Neyraud; Olivier Gisserot; Rémi Largillier; Annick Le Rol; Frank Priou; Pierre Saltel; Claire Falandry
Journal:  Clin Interv Aging       Date:  2015-07-13       Impact factor: 4.458

Review 8.  Improving outcomes for older women with gynaecological malignancies.

Authors:  Lucy Dumas; Alistair Ring; John Butler; Tania Kalsi; Danielle Harari; Susana Banerjee
Journal:  Cancer Treat Rev       Date:  2016-08-29       Impact factor: 12.111

9.  Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.

Authors:  Anthony Park; Chindu Govindaraj; Sue D Xiang; Julene Halo; Michael Quinn; Karen Scalzo-Inguanti; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2012-06-18       Impact factor: 6.639

Review 10.  Use of geriatric assessment for older adults in the oncology setting: a systematic review.

Authors:  M T E Puts; J Hardt; J Monette; V Girre; E Springall; S M H Alibhai
Journal:  J Natl Cancer Inst       Date:  2012-07-31       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.